Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Rollover Extension Phase 2 Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

NCT05407389 is registered in ClinicalTrials.gov with Kibow Pharma as lead sponsor.

NCT NCT05407389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05407389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Rollover Extension Phase 2 Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study
Lead sponsor
Kibow Pharma
Phase
Phase 2/3
Overall status
Suspended
Start date
April 21, 2022
Completion date
March 31, 2026
Enrollment
600 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stage4